Skip to content
PeptideAgent

Peptides for cardiovascular risk reduction: what the evidence shows

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

At a glance

Three GLP-1 receptor agonists have lowered major adverse cardiovascular events in large outcome trials: semaglutide (26% in SUSTAIN-6 and 20% in SELECT), liraglutide (13% in LEADER), and dulaglutide (12% in REWIND). Once weekly exenatide proved safe but not superior in EXSCEL. No research peptide has cardiovascular outcome data.

Evidence: Strongest: Human RCT evidence5 peptides gradedVerified: Verified Sep 27, 2026

Do peptides help with cardiovascular risk reduction?

5 peptides are graded for cardiovascular risk reduction on this page. The strongest grade is human RCT evidence, for semaglutide, liraglutide, dulaglutide, and exenatide. Each one is weighed against the standard of care below, and the evidence table gives the grade and a note for every peptide.

What is the standard of care for cardiovascular risk reduction?

Estimate risk with a validated calculator; lifestyle change (diet, physical activity, smoking cessation); statins and blood pressure control as the foundation; antiplatelet therapy for established disease; SGLT2 inhibitors or GLP-1 receptor agonists with proven outcome benefit for people with type 2 diabetes, and semaglutide for adults with obesity and established cardiovascular disease.

Any peptide below should be judged against this baseline, not against doing nothing. Talk to a licensed provider before replacing or adding to an established treatment.

Which peptides have been studied for cardiovascular risk reduction?

Ordered by strength of evidence for this use. Grades follow the methodology; each peptide page lists the individual studies.

Peptides studied for Cardiovascular risk reduction with evidence grades
PeptideEvidence for this useNote
SemaglutideEvidence: Human RCT evidenceSELECT (n = 17,604) found a 20% relative reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease without diabetes; Wegovy is FDA labeled for this use. [1] [2] [7]
LiraglutideEvidence: Human RCT evidenceLEADER (n = 9,340) found a 13% relative reduction in major adverse cardiovascular events in type 2 diabetes at high cardiovascular risk; Victoza is FDA labeled for this use. [3] [8]
DulaglutideEvidence: Human RCT evidenceREWIND (n = 9,901) found a 12% relative reduction in major adverse cardiovascular events in type 2 diabetes, in a population where most participants had no prior cardiovascular event. [4] [9]
ExenatideEvidence: Human RCT evidenceEXSCEL (n = 14,752) showed cardiovascular safety but the 9% lower event rate was not statistically significant. [5] [10]
HumaninEvidence: Animal-only evidenceHigher natural humanin levels tracked with better coronary endothelial function in one small study of 40 patients, but humanin has never been given to people. [6]

Head-to-head comparisons

Cost and access

Price ranges, lawful channels, and insurance notes for peptides graded here. State rules are in the legal guides by state.

Frequently asked questions

Which peptide has the strongest evidence for cardiovascular risk reduction?

Semaglutide, liraglutide, dulaglutide, and exenatide have the strongest evidence among the peptides graded here, at human RCT evidence. Semaglutide: SELECT (n = 17,604) found a 20% relative reduction in major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease without diabetes; Wegovy is FDA labeled for this use. Liraglutide: LEADER (n = 9,340) found a 13% relative reduction in major adverse cardiovascular events in type 2 diabetes at high cardiovascular risk; Victoza is FDA labeled for this use. Dulaglutide: REWIND (n = 9,901) found a 12% relative reduction in major adverse cardiovascular events in type 2 diabetes, in a population where most participants had no prior cardiovascular event. Exenatide: EXSCEL (n = 14,752) showed cardiovascular safety but the 9% lower event rate was not statistically significant. [1] [2] [7] [8]

Is any peptide FDA approved for cardiovascular risk reduction?

Semaglutide, liraglutide, dulaglutide, and exenatide are FDA approved drugs, but an approval covers only the indications on that label, so check the label before assuming it applies to cardiovascular risk reduction. The other peptides graded here are not FDA approved. [1] [2] [7] [8] [11]

Has any peptide been tested in a randomized trial for cardiovascular risk reduction?

Yes, for semaglutide, liraglutide, dulaglutide, and exenatide. Check each note for the population and endpoints: a randomized trial in a related group or on a surrogate marker is weaker than one on the outcome you care about. [1] [2] [7] [8]

From the blog

Sources

  1. [1]Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023 (SELECT)PubMed 37952131, 2023
  2. [2]Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016 (SUSTAIN-6)PubMed 27633186, 2016
  3. [3]Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER)PubMed 27295427, 2016
  4. [4]Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)PubMed 31189511, 2019
  5. [5]Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL)PubMed 28910237, 2017
  6. [6]Circulating humanin levels are associated with preserved coronary endothelial functionPubMed 23220334, 2013
  7. [7]FDA prescribing information for Wegovy (semaglutide) injection, via DailyMedFDA, 2025
  8. [8]FDA prescribing information for Saxenda (liraglutide) injection, via DailyMedFDA, 2025
  9. [9]FDA prescribing information for Trulicity (dulaglutide) injection, via DailyMedFDA, 2025
  10. [10]FDA prescribing information for Byetta (exenatide) injection, via DailyMedFDA, 2025
  11. [11]Drugs@FDA: FDA-approved drugs databaseFDA